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As of October 2021, SARS-CoV-2 has infected over 244 million people and killed about 5 million 
people. The current FDA approved vaccines are effective; however, they lose their effectiveness 
after a few months of receiving both doses of the vaccine, and it is recommended to get a booster 
shot six months after receiving the second dose of the vaccine. Therefore, new highly effective, 
long lasting antiviral agents and strategies are needed to create an alternative treatment for SARS-
CoV-2 and the different variants. Previous studies have shown that cell penetrating peptides 
(CPPs) have led to greater efficiency of intracellular delivery. However, no study is reported 
whether these peptides can be used to inhibit the viral proteins of SARS-CoV-2. The focus of this 
study is to identify cell penetrating antimicrobial peptides that have the most desirable binding 
affinities and interactions against the main protease of SARS-CoV-2. To identify these affinities 
and interaction, computational methods were employed. Peptides’ structures were modelled by 
PEP-FOLD. Molecular docking and refinement were respectively performed by PATCH-DOCK, 
and FIRE-DOCK. Peptides with the highest levels of binding affinities and interactions with the 
active site residues of HIS41 and CYS145 were selected as the best candidates. Of the peptides 
being tested, R6/W3, gH625, GALA, and TP10 have shown the highest binding affinities against 
the main protease ranging from -45.58 to -55.58 kcal/mol. These peptides will be synthesized, and 
in-vitro experiments will be performed by FRET based 3CL-protease assay. 
 
 
 
 
